Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: Comparison with other mucosal and systemic responses

Vaccine

Volumn 27, Issue 9, 2009, Pages 1386-1392

  Shamsuzzaman, Sohel ^a,b   Ahmed, Tanvir ^a,c   Mannoor, Kaiissar ^a   Begum, Yasmin Ara ^a   Bardhan, Pradip Kumar ^a   Sack, R Bradley ^d   Sack, David A ^a   Svennerholm, Ann Mari ^c   Holmgren, Jan ^c   Qadri, Firdausi ^a  

^a INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

^b UNIVERSITY OF DHAKA   (Bangladesh)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Cholera vaccine; V. cholerae O1; V. cholerae O139

Indexed keywords

CHOLERA TOXIN B SUBUNIT; CHOLERA VACCINE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY;

ADULT; ANTIBODY PRODUCTION; ARTICLE; BANGLADESH; CHOLERA; CLINICAL TRIAL; DRUG EFFECT; DRUG RESPONSE; FEVER; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; IMMUNIZATION; IMMUNOGENICITY; LYMPHOCYTE; MALE; MUCOSAL IMMUNITY; NORMAL HUMAN; PRIORITY JOURNAL; VIBRIO CHOLERAE;

ADMINISTRATION, ORAL; ADULT; ANTIBODY FORMATION; BACTERIAL VACCINES; CHOLERA VACCINES; FECES; HUMANS; IMMUNITY, MUCOSAL; MALE; SEROTYPING; SWEDEN; VACCINES, INACTIVATED; VIBRIO CHOLERAE O1; VIBRIO CHOLERAE O139;

EID: 59849117822     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.12.041     Document Type: Article

References (32)

1. Anh D.D., Canh do G., Lopez A.L., Thiem V.D., Long P.T., Son N.H., et al. Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults. Vaccine 25 6 (2007) 1149-1155
2. Trach D.D., Cam P.D., Ke N.T., Rao M.R., Dinh D., Hang P.V., et al. Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam. Bull World Health Organ 80 1 (2002) 2-8
3. Clemens J., Sack D., Rao M., Chakraborty J., Kay B., Ahmed F., et al. The design and analysis of cholera vaccine trials: recent lessons from Bangladesh. Int J Epidemiol 22 4 (1993) 724-730
4. Holmgren J., Svennerholm A.M., Jertborn M., Clemens J., Sack D.A., Salenstedt R., et al. An oral B subunit: whole cell vaccine against cholera. Vaccine 10 13 (1992) 911-914
5. Jertborn M., Svennerholm A.M., and Holmgren J. Intestinal and systemic immune responses in humans after oral immunization with a bivalent B subunit-O1/O139 whole cell cholera vaccine. Vaccine 14 15 (1996) 1459-1465
6. Thiem V.D., Deen J.L., von Seidlein L., Canh do G., Anh D.D., Park J.K., et al. Long-term effectiveness against cholera of oral killed whole-cell vaccine produced in Vietnam. Vaccine 24 20 (2006) 4297-4303
7. Mahalanabis D., Lopez A.L., Sur D., Deen J., Manna B., Kanungo S., et al. A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India. PLoS ONE 3 6 (2008) e2323
8. Jelinek T., and Kollaritsch H. Vaccination with Dukoral against travelers' diarrhea (ETEC) and cholera. Expert Rev Vaccines 7 5 (2008) 561-567
9. Jertborn M., Svennerholm A.M., and Holmgren J. Safety and immunogenicity of an oral recombinant cholera B subunit-whole cell vaccine in Swedish volunteers. Vaccine 10 2 (1992) 130-132
10. Jertborn M., Svennerholm A.M., and Holmgren J. Evaluation of different immunization schedules for oral cholera B subunit-whole cell vaccine in Swedish volunteers. Vaccine 11 10 (1993) 1007-1012
11. Clemens J.D., Stanton B.F., Chakraborty J., Sack D.A., Khan M.R., Huda S., et al. B subunit-whole cell and whole cell-only oral vaccines against cholera: studies on reactogenicity and immunogenicity. J Infect Dis 155 1 (1987) 79-85
12. Ahren C., Wenneras C., Holmgren J., and Svennerholm A.M. Intestinal antibody response after oral immunization with a prototype cholera B subunit-colonization factor antigen enterotoxigenic Escherichia coli vaccine. Vaccine 11 9 (1993) 929-934
13. Qadri F., Ahmed T., Ahmed F., Bradley Sack R., Sack D.A., and Svennerholm A.M. Safety and immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Bangladeshi children 18-36 months of age. Vaccine 21 19-20 (2003) 2394-2403
14. Wenneras C., Qadri F., Bardhan P.K., Sack R.B., and Svennerholm A.M. Intestinal immune responses in patients infected with enterotoxigenic Escherichia coli and in vaccinees. Infect Immun 67 12 (1999) 6234-6241
15. Qadri F., Ahmed F., Karim M.M., Wenneras C., Begum Y.A., Abdus Salam M., et al. Lipopolysaccharide- and cholera toxin-specific subclass distribution of B-cell responses in cholera. Clin Diagn Lab Immunol 6 6 (1999) 812-818
16. Svennerholm A.M., and Wiklund G. Rapid GM1-enzyme-linked immunosorbent assay with visual reading for identification of Escherichia coli heat-labile enterotoxin. J Clin Microbiol 17 4 (1983) 596-600
17. Jertborn M., Svennerholm A.M., and Holmgren J. Saliva, breast milk, and serum antibody responses as indirect measures of intestinal immunity after oral cholera vaccination or natural disease. J Clin Microbiol 24 2 (1986) 203-209
18. Qadri F., Svennerholm A.M., Shamsuzzaman S., Bhuiyan T.R., Harris J.B., Ghosh A.N., et al. Reduction in capsular content and enhanced bacterial susceptibility to serum killing of Vibrio cholerae O139 associated with the 2002 cholera epidemic in Bangladesh. Infect Immun 73 10 (2005) 6577-6583
19. Qadri F., Mohi G., Hossain J., Azim T., Khan A.M., Salam M.A., et al. Comparison of the vibriocidal antibody response in cholera due to Vibrio cholerae O139 Bengal with the response in cholera due to Vibrio cholerae O1. Clin Diagn Lab Immunol 2 6 (1995) 685-688
20. Qadri F., Wenneras C., Albert M.J., Hossain J., Mannoor K., Begum Y.A., et al. Comparison of immune responses in patients infected with Vibrio cholerae O139 and O1. Infect Immun 65 9 (1997) 3571-3576
21. Czerkinsky C., Moldoveanu Z., Mestecky J., Nilsson L.A., and Ouchterlony O. A novel two colour ELISPOT assay. I. Simultaneous detection of distinct types of antibody-secreting cells. J Immunol Methods 115 1 (1988) 31-37
22. Qadri F., Ryan E.T., Faruque A.S., Ahmed F., Khan A.I., Islam M.M., et al. Antigen-specific immunoglobulin A antibodies secreted from circulating B cells are an effective marker for recent local immune responses in patients with cholera: comparison to antibody-secreting cell responses and other immunological markers. Infect Immun 71 8 (2003) 4808-4814
23. Albert M.J., Qadri F., Wahed M.A., Ahmed T., Rahman A.S., Ahmed F., et al. Supplementation with zinc, but not vitamin A, improves seroconversion to vibriocidal antibody in children given an oral cholera vaccine. J Infect Dis 187 6 (2003) 909-913
24. Wenneras C., Svennerholm A.M., Ahren C., and Czerkinsky C. Antibody-secreting cells in human peripheral blood after oral immunization with an inactivated enterotoxigenic Escherichia coli vaccine. Infect Immun 60 7 (1992) 2605-2611
25. Qadri F., Makela P.H., Holmgren J., Albert M.J., Mannoor K., Kantele A., et al. Enteric infections in an endemic area induce a circulating antibody-secreting cell response with homing potentials to both mucosal and systemic tissues. J Infect Dis 177 6 (1998) 1594-1599
26. Losonsky G.A., Lim Y., Motamedi P., Comstock L.E., Johnson J.A., Morris Jr. J.G., et al. Vibriocidal antibody responses in North American volunteers exposed to wild-type or vaccine Vibrio cholerae O139: specificity and relevance to immunity. Clin Diagn Lab Immunol 4 3 (1997) 264-269
27. Clemens J.D., Sack D.A., Harris J.R., Chakraborty J., Khan M.R., Stanton B.F., et al. Field trial of oral cholera vaccines in Bangladesh. Lancet 2 8499 (1986) 124-127
28. Jertborn M., Svennerholm A.M., and Holmgren J. Gut mucosal, salivary and serum antitoxic and antibacterial antibody responses in Swedes after oral immunization with B subunit-whole cell cholera vaccine. Int Arch Allergy Appl Immunol 75 1 (1984) 38-43
29. Chowdhury F., Khan A.I., Harris J.B., LaRocque R.C., Chowdhury M.I., Ryan E.T., et al. A comparison of clinical and immunologic features in children and older patients hospitalized with severe cholera in Bangladesh. Pediatr Infect Dis J 27 11 (2008) 986-992
30. Qadri F., Chowdhury M.I., Faruque S.M., Salam M.A., Ahmed T., Begum Y.A., et al. Randomized, controlled study of the safety and immunogenicity of Peru-15, a live attenuated oral vaccine candidate for cholera, in adult volunteers in Bangladesh. J Infect Dis 192 4 (2005) 573-579
31. Faruque S.M., Sack D.A., Sack R.B., Colwell R.R., Takeda Y., and Nair G.B. Emergence and evolution of Vibrio cholerae O139. Proc Natl Acad Sci USA 100 3 (2003) 1304-1309
32. John T.J. Emerging & re-emerging bacterial pathogens in India. Indian J Med Res 103 (1996) 4-18